|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4184 | |
| A61K 9/00 | |||
| A61K 9/08 | |||
| A61P 27/06 |
| (11) | Number of the document | 2525793 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11702342.4 |
| Date of filing the European patent application | 2011-01-21 | |
| (97) | Date of publication of the European application | 2012-11-28 |
| (45) | Date of publication and mention of the grant of the patent | 2018-09-05 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2011/022001 |
| Date | 2011-01-21 |
| (87) | Number | WO 2011/091225 |
| Date | 2011-07-28 |
| (30) | Number | Date | Country code |
| 296912 P | 2010-01-21 | US |
| (72) |
DONELLO, John E., US
GIL, Daniel W., US
DIBAS, Mohammed I., US
|
| (73) |
ALLERGAN, INC.,
2525 Dupont Drive, Irvine, CA 92612,
US
|
| (54) | Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |
| Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect |